The second cannabinoid receptor (CB2) is found on most cells of the immune system where it has predominantly inhibitory actions, CB2 activation has predominantly anti-inflammatory activity.[1][2] It is also expressed on the support cells of the brain, where it also exhibits anti-inflammatory actions.[3] CB2 activity is also involved in non-alcoholic fatty liver disease.[4] A possible role in bone health has also been proposed based on the fact it is known to be expressed on the cells of the body that mediate bone growth, repair and renewal.[5] Animal studies have seemed to support a role for both CB1 and CB2 in bone health.[5]

Reference listEdit

  1. Svízenská, I; Dubový, P; Sulcová, A (October 2008). "Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.". Pharmacology, Biochemistry, and Behavior 90 (4): 501–11. doi:10.1016/j.pbb.2008.05.010. PMID 18584858.
  2. Basu, S; Dittel, BN (October 2011). "Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease.". Immunologic Research 51 (1): 26–38. doi:10.1007/s12026-011-8210-5. PMID 21626285.
  3. Cabral, GA; Raborn, ES; Griffin, L; Dennis, J; Marciano-Cabral, F (January 2008). "CB2 receptors in the brain: role in central immune function.". British Journal of Pharmacology 153 (2): 240–51. doi:10.1038/sj.bjp.0707584. PMC 2219530. PMID 18037916.
  4. Alswat, KA (July-August 2013). "The role of endocannabinoids system in fatty liver disease and therapeutic potentials.". Saudi Journal of Gastroenterology 19 (4): 144–51. doi:10.4103/1319-3767.114505. PMC 3745655. PMID 23828743.
  5. 5.0 5.1 Idris, AI (November 2012). "The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease.". BoneKEy Reports 1: 224. doi:10.1038/bonekey.2012.224. PMC 3868875. PMID 24363927.